WO2001070768A3 - Receptor-binding compounds and method for identifying them - Google Patents

Receptor-binding compounds and method for identifying them Download PDF

Info

Publication number
WO2001070768A3
WO2001070768A3 PCT/US2001/009160 US0109160W WO0170768A3 WO 2001070768 A3 WO2001070768 A3 WO 2001070768A3 US 0109160 W US0109160 W US 0109160W WO 0170768 A3 WO0170768 A3 WO 0170768A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding compounds
identifying
receptor
compounds
chemokine receptor
Prior art date
Application number
PCT/US2001/009160
Other languages
French (fr)
Other versions
WO2001070768A2 (en
Inventor
John J Nestor Jr
Carol J Wilson
Hehir Christina A Tan
Steven A Kates
Original Assignee
Consensus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/813,653 external-priority patent/US20020064770A1/en
Priority claimed from US09/813,448 external-priority patent/US20020142346A1/en
Priority claimed from US09/813,651 external-priority patent/US20030018438A1/en
Application filed by Consensus Pharmaceuticals Inc filed Critical Consensus Pharmaceuticals Inc
Priority to EP01920643A priority Critical patent/EP1268520A2/en
Priority to AU2001247675A priority patent/AU2001247675A1/en
Priority to CA002403784A priority patent/CA2403784A1/en
Publication of WO2001070768A2 publication Critical patent/WO2001070768A2/en
Publication of WO2001070768A3 publication Critical patent/WO2001070768A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)

Abstract

Compositions of binding compounds for CXC chemokine receptor 4 and methods for identifying binding compounds for CXC chemokine receptor 4 are provided. Also provided are therapeutic agents comprising such compounds.
PCT/US2001/009160 2000-03-21 2001-03-21 Receptor-binding compounds and method for identifying them WO2001070768A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01920643A EP1268520A2 (en) 2000-03-21 2001-03-21 Receptor-binding compounds and methods for identifying them
AU2001247675A AU2001247675A1 (en) 2000-03-21 2001-03-21 Binding compounds and methods for identifying binding compounds
CA002403784A CA2403784A1 (en) 2000-03-21 2001-03-21 Binding compounds and methods for identifying binding compounds

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US19099600P 2000-03-21 2000-03-21
US19094600P 2000-03-21 2000-03-21
US19129900P 2000-03-21 2000-03-21
US60/190,996 2000-03-21
US60/191,299 2000-03-21
US60/190,946 2000-03-21
US09/813,653 US20020064770A1 (en) 2000-03-21 2001-03-20 Binding compounds and methods for identifying binding compounds
US09/813,448 US20020142346A1 (en) 2000-03-21 2001-03-20 Binding compounds and methods for identifying binding compounds
US09/813,651 US20030018438A1 (en) 2000-03-21 2001-03-20 Binding compounds and methods for identifying binding compounds
US09/813,448 2001-03-20
US09/813,653 2001-03-20
US09/813,651 2001-03-20

Publications (2)

Publication Number Publication Date
WO2001070768A2 WO2001070768A2 (en) 2001-09-27
WO2001070768A3 true WO2001070768A3 (en) 2002-03-14

Family

ID=27558818

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2001/040345 WO2001070765A1 (en) 2000-03-21 2001-03-21 Receptor-binding compounds and methods for identifying them
PCT/US2001/009160 WO2001070768A2 (en) 2000-03-21 2001-03-21 Receptor-binding compounds and method for identifying them
PCT/US2001/009155 WO2001071346A2 (en) 2000-03-21 2001-03-21 Binding compounds for cc chemokine receptor 5 and methods for identifying them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040345 WO2001070765A1 (en) 2000-03-21 2001-03-21 Receptor-binding compounds and methods for identifying them

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009155 WO2001071346A2 (en) 2000-03-21 2001-03-21 Binding compounds for cc chemokine receptor 5 and methods for identifying them

Country Status (5)

Country Link
EP (3) EP1268520A2 (en)
JP (2) JP2003528319A (en)
AU (3) AU2001247675A1 (en)
CA (3) CA2403784A1 (en)
WO (3) WO2001070765A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056581A2 (en) * 2003-12-10 2005-06-23 Universite De Lausanne Peptide able to specifically bind a chemokine receptor and use thereof
CN101036057A (en) * 2004-10-04 2007-09-12 阿尔卡米亚有限公司 Selective inhibitors
GB0724860D0 (en) * 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
US8409837B2 (en) * 2010-08-19 2013-04-02 Probiodrug Ag Crystal structure of glutaminyl cyclase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532167A (en) * 1994-01-07 1996-07-02 Beth Israel Hospital Substrate specificity of protein kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532167A (en) * 1994-01-07 1996-07-02 Beth Israel Hospital Substrate specificity of protein kinases

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
FURKA A: "Sub-library composition of peptide libraries: Potential application in screening", DRUG DEVELOPMENT RESEARCH,US,NEW YORK, NY, vol. 33, 1994, pages 90 - 97, XP000672923, ISSN: 0272-4391 *
GALLOP M A ET AL: "Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 37, no. 9, 29 April 1994 (1994-04-29), pages 1233 - 1251, XP000195952, ISSN: 0022-2623 *
LOETSCHER ET AL: "N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 35, 28 August 1998 (1998-08-28), pages 22279 - 22283, XP002115696, ISSN: 0021-9258 *
LUO ET AL: "The role of positively charged residues in CXCR4 recognition probed with synthetic peptides", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 263, 1999, pages 691 - 695, XP002169962 *
PALCZEWSKI ET AL: "Crystal structure of rhodopsin: A G protein-coupled receptor", SCIENCE, vol. 289, August 2000 (2000-08-01), pages 739 - 745, XP002169964 *
SMITH G P ET AL: "Phage Display", CHEMICAL REVIEWS,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 97, no. 2, 1 March 1997 (1997-03-01), pages 391 - 410, XP000683275, ISSN: 0009-2665 *
TAMAMURA ET AL: "A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 253, 1998, pages 877 - 882, XP002169961 *
WEST M L ET AL: "Targeting HIV-1 protease: a test of drug-design methodologies", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 16, no. 2, February 1995 (1995-02-01), pages 67 - 75, XP004207457, ISSN: 0165-6147 *
WILKEN H-C ET AL: "Specific detection by flow cytometry of histidine-tagged ligands bound to their receptors using a tag-specific monoclonal antibody", JOURNAL OF IMMUNOLOGICAL METHODS,NL,ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, vol. 226, no. 1-2, 24 June 1999 (1999-06-24), pages 139 - 145, XP004171367, ISSN: 0022-1759 *
ZHOU ET AL: "A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II", BIOCHEMISTRY, vol. 39, April 2000 (2000-04-01), pages 3782 - 3787, XP002169963 *

Also Published As

Publication number Publication date
CA2403784A1 (en) 2001-09-27
WO2001070765A1 (en) 2001-09-27
CA2403788A1 (en) 2001-09-27
AU2001247674A1 (en) 2001-10-03
CA2404139A1 (en) 2001-09-27
WO2001070768A2 (en) 2001-09-27
JP2003528319A (en) 2003-09-24
WO2001071346A2 (en) 2001-09-27
JP2004502134A (en) 2004-01-22
EP1268520A2 (en) 2003-01-02
WO2001070765A9 (en) 2003-02-06
WO2001071346A3 (en) 2002-09-12
AU2001247675A1 (en) 2001-10-03
AU2001253870A1 (en) 2001-10-03
EP1268523A2 (en) 2003-01-02
EP1268521A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
DZ3191A1 (en) Indazole compounds and pharmaceutical compositions inhibiting protein kinases, and methods of using the same.
SK157899A3 (en) Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions
GB2371557B (en) Method for the preparation of hydrogenated hydrocarbons
GR3030407T3 (en) Naphthyl compounds, intermediates, compositions, and methods
ZA975947B (en) Aqueous-based pharmaceutical composition.
AU3725300A (en) Interleukin 17 receptor-like protein
AU6497600A (en) Peracid forming system, peracid forming composition, and methods for making and using
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
GB9903216D0 (en) Preservative compounds,compositions and methods of making and using the same
AU2002366644A1 (en) Method for administering birb 796 bs
CY2408B1 (en) Paroxetine controlled release compositions.
HUP0000167A3 (en) Pyrroles as spla2 inhibitors, and pharmaceutical compositions containing them
AU2001271502A1 (en) Methods and compositions for isolating biologically active antibodies
AU2001245987A1 (en) Compositions and methods for gene therapy
AU5038800A (en) Copper source reagent compositions, and method of making and using same for microelectronic device structures
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
PL352432A1 (en) Neurothrophic pyrolydines and piperidines, their affinite composition and methods of using them
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
WO2002057313A8 (en) Receptor-binding compounds and methods for identifying them
HUP0001551A3 (en) Improved method for producing thiazolidinediones, thiazolidinediones and pharmaceutical compositions containing the same
DK0791591T3 (en) Benzothiophenes, formulations containing the same and methods for their preparation
AU2002332598A1 (en) Compositions and methods for generating antigen-binding units
WO2001070768A3 (en) Receptor-binding compounds and method for identifying them
NO990913D0 (en) Naphthyl compounds, intermediates, compositions and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 568969

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2403784

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001247675

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001920643

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001920643

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001920643

Country of ref document: EP